Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Viba Therapeutics

2016 FOUNDED
PRIVATE STATUS
Early Stage VC LATEST DEAL TYPE
2 INVESTORS
Description

Developer of monoclonal antibodies created to treat solid tumors. The company's monoclonal antibody, Viba mAbs, target a validated pathway which initiates and drives the progression and metastasis of numerous malignancies and effect substantial increases in overall survival and tumor regression as single-agent therapy in highly-stringent animal models of advanced cancer which is refractory to standard-of-care treatment.

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Other Healthcare Services
Other Industries
Biotechnology
Drug Discovery
Primary Office
  • 1700 Owens Street
  • Suite 515
  • San Francisco, CA 94158
  • United States
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Viba Therapeutics’s full profile, request a free trial.

Viba Therapeutics Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Early Stage VC 26-Apr-2016 Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

Viba Therapeutics Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Potrero Hill Therapeutics Venture Capital Minority 000 0000 000000 0
RiverVest Venture Partners Venture Capital Minority 000 0000 000000 0

Viba Therapeutics Board Members (1)

Name Representing Role Since Contact
Info
John McKearn Ph.D RiverVest Venture Partners Board Member 000 0000